Cooperative Agreement UG3DA064392
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$3.1M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10014, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $11,872,077 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Sparian Biosciences Inc. (doing business as Palion Therapeutics) to develop SBS-226, a novel chemical entity that acts as a mu-opioid receptor agonist and delta-opioid receptor antagonist, for the treatment of opioid use disorder (OUD). The project aims to advance SBS-226 through IND-enabling studies and a Phase 1 clinical trial. Sparian...
The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $23,579,701 Cooperative Agreement to Ensysce Biosciences, Inc. to continue the clinical development of PF614-MPAR, an opioid product with overdose protection. PF614-MPAR is a combination product that includes a trypsin-activated abuse-resistant oxycodone prodrug (PF614) and the trypsin inhibitor nafamostat, which provides overdose protection. The goal of this award is to...
This SBIR Phase II award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,776,138 to Neurocarrus Inc. to develop a novel biologic drug called N-001 for the management of acute nociceptive pain. The funding will be used to optimize the production and formulation of N-001, establish manufacturing standards and controls, and conduct pivotal preclinical studies to demonstrate the safety and...
The National Institute on Drug Abuse (NIDA) awarded a $220,668 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Amalgent Therapeutics, Inc. in Greenville, NC. This grant supports the development of a novel opioid adjuvant technology that aims to enhance the pain-relieving efficacy of opioid medications while mitigating risks such as abuse potential, tolerance, and neuropathic pain. The project has two key objectives: 1) investigating the mechanism by which the...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $19,302,777 to Nirsum Laboratories, Inc. to accelerate the development of NRS-033, a long-acting injectable medication for opioid use disorder (OUD). The key products and services to be delivered under this award include late-stage chemistry, manufacturing, and controls (CMC) for the active pharmaceutical ingredient (API) and drug...
This Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $9,275,866 to the University of North Carolina at Chapel Hill to develop small molecule compounds that engage a non-opioid G protein-coupled receptor (GPCR) in brain regions associated with the unpleasant affective aspects of pain perception. The goal is to create safer analgesics that can reduce pain...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,593,126 to Dimerx, Inc. to rigorously evaluate the safety and efficacy of their non-addictive, peripherally acting opioid analgesic compound DMX-101 through various preclinical and clinical phases. The key products and services to be delivered include: Assessing the abuse liability potential of DMX-101 in rats, demonstrating that it does...
This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,106,020 Cooperative Agreement under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Lutroo Imaging LLC to develop Radiocaine, a novel positron emission tomography (PET) imaging agent, as a biomarker to objectively measure pain signals. The project aims to transform pain assessment and therapy development by enabling rapid, accurate localization and quantification of pain generators. The ultimate...